Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum

**Version:** Colon Rectum 4.0.0.0  
**Protocol Posting Date:** June 2017  
Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colectomy</td>
<td>Includes specimens designated total, partial, or segmental resection</td>
</tr>
<tr>
<td>Rectal Resection</td>
<td>Includes specimens designated low anterior resection or abdominoperineal resection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma</td>
<td>Invasive carcinomas including small cell and large cell (poorly differentiated) neuroendocrine carcinoma</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excisional biopsy (polypectomy)</td>
</tr>
<tr>
<td>Local excision (transanal disk excision)</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated neuroendocrine tumors (consider the Colorectal NET protocol)</td>
<td></td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocol)</td>
<td></td>
</tr>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
<td></td>
</tr>
</tbody>
</table>

Authors

Sanjay Kakar, MD*; Chanjuan Shi MD, PhD*; Mariana E. Berho, MD, PhD; David K. Driman, MBchB; Patrick Fitzgibbons, MD; Wendy L. Frankel, MD; Kalisha A. Hill, MD, MBA; John Jessup, MD; Alyssa M. Krasinskas, MD; Mary K Washington, MD, PhD

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author. All other contributing authors are listed alphabetically.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined."

- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.

- **Optional data elements** are identified with "+" and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Transanal disk excision is NOT considered to be the definitive resection specimen for the purpose of cancer reporting, even though the entire cancer may be removed. A protocol is recommended for reporting such specimens for clinical care purposes, but this is not required for accreditation purposes.

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired "Data element: Response" format is NOT considered synoptic.

- The data element must be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including "Cannot be determined" if appropriate.

- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable

- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.

**CAP Laboratory Accreditation Program Protocol Required Use Date: March 2018**
*Beginning January 1, 2018, the 8th edition AJCC Staging Manual should be used for reporting pTNM.*

**CAP Colon and Rectum Protocol Summary of Changes**

The following data elements were modified:
Pathologic Stage Classification (pTNM, AJCC 8th Edition)
Histologic Type
Histologic Grade
Type of Polyp in Which Invasive Carcinoma Arose
Additional Pathological Findings

The following data element was added:
Tumor budding
Resection, Including Transanal Disk Excision of Rectal Neoplasms

The following data elements were modified:
- Histologic Type
- Histologic Grade
- Tumor Extension
- Margins
- Pathologic Stage Classification (pTNM, AJCC 8th Edition)
- Type of Polyp in Which Invasive Carcinoma Arose
- Additional Pathologic Findings

The following data element was added:
- Peritumoral tumor budding

The following data element was removed:
- Histologic Features Suggestive of Microsatellite Instability
Surgical Pathology Cancer Case Summary

Protocol posting date: June 2017

COLON AND RECTUM: Excisional Biopsy (Polypectomy)

Note: This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes.

Select a single response unless otherwise indicated.

Tumor Site (Note A)

___ Cecum
___ Ileocecal valve
___ Right (ascending) colon
___ Hepatic flexure
___ Transverse colon
___ Splenic flexure
___ Left (descending) colon
___ Sigmoid colon
___ Rectosigmoid region
___ Rectum
___ Other (specify): ________________________
___ Not specified

+ Specimen Integrity
+ ___ Intact
+ ___ Fragmented

+ Polyp Size
+ Greatest dimension (centimeters): ___ cm
+ Additional dimensions (centimeters): ___ x ___ cm
+ ___ Cannot be determined (explain): _______________________________

+ Polyp Configuration
+ ___ Pedunculated with stalk
  + Stalk length (centimeters): ___ cm
+ ___ Sessile

+ Size of Invasive Carcinoma
+ Greatest dimension (centimeters): ___ cm
+ Additional dimensions (centimeters): ___ x ___ cm
+ ___ Cannot be determined (explain): _______________________________

Histologic Type (select all that apply) (Note B)

___ Adenocarcinoma
___ Mucinous adenocarcinoma
___ Signet-ring cell carcinoma
___ Medullary carcinoma
___ Micropapillary carcinoma
___ Serrated adenocarcinoma
___ Large cell neuroendocrine carcinoma
___ Small cell neuroendocrine carcinoma
___ Neuroendocrine carcinoma (poorly differentiated)
___ Squamous cell carcinoma

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
___ Adenosquamous carcinoma
___ Spindle cell carcinoma
___ Mixed adenoneuroendocrine carcinoma
___ Undifferentiated carcinoma
___ Other histologic type not listed (specify): __________________________
___ Carcinoma, type cannot be determined

# Note: Select this option only if large cell or small cell cannot be determined

**Histologic Grade (Note C)**
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated
___ G4: Undifferentiated
___ Other (specify): __________________________
___ GX: Cannot be assessed
___ Not applicable

**Tumor Extension (Note D)**
___ Tumor invades lamina propria
___ Tumor invades muscularis mucosae
___ Tumor invades submucosa
___ Tumor invades muscularis propria
___ Cannot be assessed

**Margins (select all that apply)**

**Deep Margin (Stalk Margin)**
___ Cannot be assessed
___ Uninvolved by invasive carcinoma
___ Involved by invasive carcinoma

Distance of invasive carcinoma from margin (millimeters or centimeters): ___ mm or ___ cm

**Mucosal Margin (required only if applicable)**
___ Cannot be assessed
___ Uninvolved by invasive carcinoma
___ Involved by invasive carcinoma
___ Involved by adenoma

**Lymphovascular Invasion (Notes D and E)**
___ Not identified
___ Present
  + ___ Small vessel lymphovascular invasion
  + ___ Large vessel (venous) invasion
___ Cannot be determined

**Tumor Budding (Note F)**
+ ___ Number of tumor buds in 1 “hotspot” field (e specify total number in area=0.785 mm²): __________
  + ___ Low score (0-4)
  + ___ Intermediate score (5-9)
  + ___ High score (10 or more)
+ ___ Cannot be determined

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
<table>
<thead>
<tr>
<th>+ Type of Polyp in Which Invasive Carcinoma Arose (Note G)</th>
</tr>
</thead>
<tbody>
<tr>
<td>+ tubular adenoma</td>
</tr>
<tr>
<td>+ villous adenoma</td>
</tr>
<tr>
<td>+ tubulovillous adenoma</td>
</tr>
<tr>
<td>+ traditional serrated adenoma</td>
</tr>
<tr>
<td>+ sessile serrated adenoma/sessile serrated polyp</td>
</tr>
<tr>
<td>+ hamartomatous polyp</td>
</tr>
<tr>
<td>+ other (specify): ___________________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>+ Additional Pathologic Findings (select all that apply)</th>
</tr>
</thead>
<tbody>
<tr>
<td>+ none identified</td>
</tr>
<tr>
<td>+ ulcerative colitis</td>
</tr>
<tr>
<td>+ crohn disease</td>
</tr>
<tr>
<td>+ other polyps (type[s]): ______________________________</td>
</tr>
<tr>
<td>+ other (specify): ___________________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>+ Ancillary Studies (Note N)</th>
</tr>
</thead>
</table>

*Note:* For reporting molecular testing and immunohistochemistry for mismatch repair proteins, and for other cancer biomarker testing results, the CAP Colorectal Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.

<table>
<thead>
<tr>
<th>+ Comment(s)</th>
</tr>
</thead>
</table>
Surgical Pathology Cancer Case Summary

Protocol posting date: June 2017

COLON AND RECTUM: Resection, Including Transanal Disk Excision of Rectal Neoplasms

Note: This case summary is recommended for reporting transanal disc excision specimens, but is not required for accreditation purposes.

Select a single response unless otherwise indicated.

Procedure
___ Right hemicolectomy
___ Transverse colectomy
___ Left hemicolectomy
___ Sigmoidectomy
___ Low anterior resection
___ Total abdominal colectomy
___ Abdominoperineal resection
___ Transanal disk excision (local excision)
___ Endoscopic mucosal resection
___ Other (specify): ____________________________
___ Not specified

Tumor Site (select all that apply) (Note A)
___ Cecum
___ Ileocecal valve
___ Right (ascending) colon
___ Hepatic flexure
___ Transverse colon
___ Splenic flexure
___ Left (descending) colon
___ Sigmoid colon
___ Rectosigmoid region
___ Rectum
___ Colon, not otherwise specified
___ Cannot be determined (explain): _______________________________

+ Tumor Location (applicable only to rectal primaries) (Note A)
+ ___ Entirely above the anterior peritoneal reflection
+ ___ Entirely below the anterior peritoneal reflection
+ ___ Straddles the anterior peritoneal reflection
+ ___ Not specified

Tumor Size
Greatest dimension (centimeters): ___ cm
+ Additional dimensions (centimeters): ___ x ___ cm
___ Cannot be determined (explain): _______________________________

Macroscopic Tumor Perforation (Note H)
___ Not identified
___ Present
___ Cannot be determined

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
+ Macroscopic Intactness of Mesorectum (if applicable) (Note I)
+ ___ Complete
+ ___ Near complete
+ ___ Incomplete
+ ___ Cannot be determined

Histologic Type (Note B)
___ Adenocarcinoma
___ Mucinous adenocarcinoma
___ Signet-ring cell carcinoma
___ Medullary carcinoma
___ Micropapillary carcinoma
___ Serrated adenocarcinoma
___ Large cell neuroendocrine carcinoma
___ Small cell neuroendocrine carcinoma
___ Neuroendocrine carcinoma (poorly differentiated) *
___ Squamous cell carcinoma
___ Adenosquamous carcinoma
___ Undifferentiated carcinoma
___ Other histologic type not listed (specify): ____________________________
___ Carcinoma, type cannot be determined

* Note: Select this option only if large cell or small cell cannot be determined

Histologic Grade (Note C)
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated
___ G4: Undifferentiated
___ Other (specify): ____________________________
___ GX: Cannot be assessed
___ Not applicable

Tumor Extension
___ No evidence of primary tumor
___ No invasion (high-grade dysplasia)
___ Tumor invades lamina propria/muscularis mucosae (intramucosal carcinoma)
___ Tumor invades submucosa
___ Tumor invades muscularis propria
___ Tumor invades through the muscularis propria into pericolorectal tissue
___ Tumor invades the visceral peritoneum (including tumor continuous with serosal surface through area of inflammation)
___ Tumor directly invades adjacent structures (specify: ____________________) 
___ Cannot be assessed

Margins (Note J)
Note: Use this section only if all margins are uninvolved and all margins can be assessed.
___ All margins are uninvolved by invasive carcinoma, high-grade dysplasia, intramucosal adenocarcinoma, and adenoma

Margins examined: ____________________

Note: Margins may include proximal, distal, radial or mesenteric, deep, mucosal, and others.
___ Distance of invasive carcinoma from closest margin (millimeters or centimeters): ___ mm or ___ cm
___ Specify closest margin: ____________________

Distance of tumor from radial margin (required only for rectal tumors) (millimeters or centimeters):
___ mm or ___ cm

* Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
+ Distance of tumor from distal margin (recommended for rectal tumors) (millimeters or centimeters):
  ___ mm or ___ cm

*Individual margin reporting required if any margins are involved or margin involvement cannot be assessed*

_For resection specimens only_

**Proximal Margin**
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma
  + Distance of tumor from margin: ___ mm or ___ cm
- ___ Involved by invasive carcinoma

**Distal Margin**
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma
  + Distance of tumor from margin (millimeters or centimeters): ___ mm or ___ cm
- ___ Involved by invasive carcinoma (tumor present 0-1 mm from margin)

**Radial or Mesenteric Margin**
- ___ Not applicable
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma
  + Distance of tumor from margin (required only for rectal tumors) (millimeters or centimeters):
    ___ mm or ___ cm
- ___ Involved by invasive carcinoma (tumor present 0-1 mm from margin)

**Other Margin(s) (required only if applicable)**
Specify margin(s): __________________________
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma
- ___ Involved by invasive carcinoma

_For transanal disk excision specimens only_

**Deep Margin**
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma
  + Distance of tumor from margin: ___ mm or ___ cm
- ___ Involved by invasive carcinoma

**Mucosal Margin**
- ___ Cannot be assessed
- ___ Uninvolved by invasive carcinoma, intramucosal adenocarcinoma, high-grade dysplasia, and adenoma
  + Distance of invasive carcinoma from closest mucosal margin (millimeters or centimeters):
    ___ mm or ___ cm
  + Specify location (eg, o’clock position), if possible: __________________________
- ___ Involved by invasive carcinoma
  + Distance of invasive carcinoma from closest mucosal margin (millimeters or centimeters):
    ___ mm or ___ cm
  + Specify location (eg, o’clock position), if possible: __________________________
     Involved by:
     ___ Intramucosal adenocarcinoma
     + Specify location (eg, o’clock position), if possible: __________________________
     ___ High-grade dysplasia
     + Specify location (eg, o’clock position), if possible: __________________________

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
___ Adenoma
    + Specify location (eg, o’clock position), if possible: ___________________

___ Involved by invasive carcinoma
    + Specify location (eg, o’clock position), if possible: ___________________

___ Uninvolved by intramucosal adenocarcinoma, high-grade dysplasia, and adenoma

OR

Involved by:
___ Intramucosal adenocarcinoma
    + Specify location (eg, o’clock position), if possible: ___________________

___ High-grade dysplasia
    + Specify location (eg, o’clock position), if possible: ___________________

___ Adenoma
    + Specify location (eg, o’clock position), if possible: ___________________

Treatment Effect (Note K)
___ No known presurgical therapy

___ Present
    + ___ No viable cancer cells (complete response, score 0)
    + ___ Single cells or rare small groups of cancer cells (near complete response, score 1)
    + ___ Residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response, score 2)

___ Absent
    + ___ Extensive residual cancer with no evident tumor regression (poor or no response, score 3)

___ Cannot be determined

Lymphovascular Invasion (Note E)
___ Not identified

___ Present
    + ___ Small vessel lymphovascular invasion
    + ___ Large vessel (venous) invasion
    + ___ Intramural
    + ___ Extramural

___ Cannot be determined

Perineural Invasion (Note E)
___ Not identified

___ Present

___ Cannot be determined

+ Tumor Budding (Note F)
+ ___ Number of tumor buds in 1 “hotspot” field (specify total number in area=0.785 mm²): __________
    + ___ Low score (0-4)
    + ___ Intermediate score (5-9)
    + ___ High score (10 or more)

+ ___ Cannot be determined

+ Type of Polyp in Which Invasive Carcinoma Arose (Note G)
+ ___ None identified
+ ___ Tubular adenoma
+ ___ Villous adenoma
+ ___ Tubulovillous adenoma
+ ___ Traditional serrated adenoma
+ ___ Sessile serrated adenoma/sessile serrated polyp
+ ___ Hamartomatous polyp
+ ___ Other (specify): ____________________

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
### Tumor Deposits (Note L)

- Not identified
- Present
  - Specify number of deposits: __
  - Number cannot be determined (explain): __________________
- Cannot be determined

### Regional Lymph Nodes

- No lymph nodes submitted or found

#### Lymph Node Examination (required only if lymph nodes present in specimen)

- Number of Lymph Nodes Involved: __
  - Number cannot be determined (explain): __________________
- Number of Lymph Nodes Examined: __
  - Number cannot be determined (explain): __________________

### Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note M)

*Note:* Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be included in the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line.

#### TNM Descriptors (required only if applicable) (select all that apply)

- m (multiple primary tumors)
- r (recurrent)
- y (posttreatment)

#### Primary Tumor (pT)

- pTX: Primary tumor cannot be assessed
- pT0: No evidence of primary tumor
- pTis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae)
- pT1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria)
- pT2: Tumor invades the muscularis propria
- pT3: Tumor invades through the muscularis propria into pericolorectal tissues
- pT4: Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or structure
  - pT4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum)
  - pT4b: Tumor directly invades or adheres to adjacent organs or structures

#### Regional Lymph Nodes (pN)

- pNX: Regional lymph nodes cannot be assessed
- pN0: No regional lymph node metastasis
- pN1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring ≥0.2 mm), or any number of tumor deposits are present and all identifiable lymph nodes are negative
  - pN1a: One regional lymph node is positive
  - pN1b: Two or three regional lymph nodes are positive
  - pN1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues.
- pN2: Four or more regional lymph nodes are positive
  - pN2a: Four to six regional lymph nodes are positive
  - pN2b: Seven or more regional lymph nodes are positive

*Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.*
Distant Metastasis (pM) (required only if confirmed pathologically in this case)
___ pM1: Metastasis to one or more distant sites or organs or peritoneal metastasis is identified
___ pM1a: Metastasis to one site or organ is identified without peritoneal metastasis
___ pM1b: Metastasis to two or more sites or organs is identified without peritoneal metastasis
___ pM1c: Metastasis to the peritoneal surface is identified alone or with other site or organ metastases

Specify site(s), if known: ______________________________

+ Additional Pathologic Findings (select all that apply)
+ ___ None identified
+ ___ Adenoma(s)
+ ___ Ulcerative colitis
+ ___ Crohn disease
+ ___ Diverticulosis
+ ___ Dysplasia arising in inflammatory bowel disease
+ ___ Other polyps (type[s]): ___________________________
+ ___ Other (specify): ___________________________

+ Ancillary Studies (Note N)

Note: For reporting molecular testing and immunohistochemistry for mismatch repair proteins, and for other cancer biomarker testing results, the CAP Colorectal Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.

+ Comment(s)
Explanatory Notes

A. Anatomic Sites
The protocol applies to all carcinomas arising in the colon and rectum.¹ It excludes carcinomas of the vermiform appendix and low-grade neuroendocrine neoplasms (carcinoid tumors).

The colon is divided as shown in Figure 1. The right colon is subdivided into the cecum and the ascending colon.² The left colon is subdivided into the descending colon and sigmoid colon (see Table 1).¹

![Figure 1. Anatomic subsites of the colon. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al² and published by Springer Science and Business Media, LLC, www.springerlink.com.]

![Table 1. Anatomic Subsites of the Colon and Rectum](image)

<table>
<thead>
<tr>
<th>Site</th>
<th>Relationship to Peritoneum (see Note J)</th>
<th>Dimensions (approximate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cecum</td>
<td>Entirely covered by peritoneum</td>
<td>6 x 9 cm</td>
</tr>
<tr>
<td>Ascending colon</td>
<td>Retroperitoneal; posterior surface lacks peritoneal covering; lateral and anterior surfaces covered by visceral peritoneum (serosa)</td>
<td>15-20 cm long</td>
</tr>
<tr>
<td>Transverse colon</td>
<td>Intraperitoneal; has mesentery</td>
<td>Variable</td>
</tr>
<tr>
<td>Descending colon</td>
<td>Retroperitoneal; posterior surface lacks peritoneal covering; lateral and anterior surfaces covered by visceral peritoneum (serosa)</td>
<td>10-15 cm long</td>
</tr>
<tr>
<td>Sigmoid colon</td>
<td>Intraperitoneal; has mesentery</td>
<td>Variable</td>
</tr>
<tr>
<td>Rectum</td>
<td>Upper third covered by peritoneum on anterior and lateral surfaces; middle third covered by peritoneum only on anterior surface; lower third has no peritoneal covering</td>
<td>12 cm long</td>
</tr>
</tbody>
</table>

The transition from sigmoid to rectum is marked by the fusion of the tenia coli of the sigmoid to form the circumferential longitudinal muscle of the rectal wall approximately 12 to 15 cm from the dentate line. The rectum is defined clinically as the distal large intestine commencing opposite the sacral promontory and ending at the anorectal ring, which corresponds to the proximal border of the puborectalis muscle palpable on digital rectal examination¹ (Figure 2). When measuring below with a rigid sigmoidoscope, it extends 16 cm from the anal verge.
Figure 2. Anatomic subsites of the rectum. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al and published by Springer Science and Business Media, LLC, www.springerlink.com.

Tumors located at the border between two subsites of the colon (e.g., cecum and ascending colon) are registered as tumors of the subsite that is more involved. If two subsites are involved to the same extent, the tumor is classified as an "overlapping" lesion.

A tumor is classified as rectal if its inferior margin lies less than 16 cm from the anal verge or if any part of the tumor is located at least partly within the supply of the superior rectal artery. The rectum commences at the sacral promontory, and the junction of sigmoid colon and rectum is anatomically marked by fusion of tenia coli to form the circumferential longitudinal muscle of the rectal wall. Intraoperatively, the rectosigmoid junction corresponds to the sacral promontory. A tumor is classified as rectosigmoid when differentiation between rectum and sigmoid according to the previously mentioned guidelines is not possible.

Anteriorly, the peritoneal reflection is located at the junction of middle and lower third of the rectum, while laterally, it is located at the junction of upper and middle third of the rectum. Posteriorly, the reflection is located higher and most of the posterior rectum does not have a serosal covering.

(a) Whether an adenocarcinoma located in the rectum has a circumferential resection (radial) margin (CRM) or a peritoneal (serosal) surface depends on its location in relation to the peritoneal reflections. Tumors below the anterior peritoneal reflection will have a 360-degree CRM, while those above it may have a CRM or a peritoneal (serosal) surface, or both, depending on the precise location.

(b) Neoadjuvant therapy and mesorectal excision are considered standard of care for rectal adenocarcinomas "below the anterior peritoneal reflection," while the opinions about use of these modalities vary about rectal adenocarcinomas located above the anterior peritoneal reflection. Conservative options like transanal disc excisions are often considered for location “below the anterior peritoneal reflection.” In these contexts, the peritoneal reflection refers to the junction of upper and middle third of the rectum; there is ongoing debate in the surgical literature about the concept of peritoneal reflection. If information about tumor location with respect to the peritoneal reflection is included in the report, the aspect of rectum in question (posterior, lateral, anterior) should also be noted.
B. Histologic Types
For consistency in reporting, the histologic classification proposed by the World Health Organization (WHO) is recommended and is shown below.\(^6\)

**WHO Classification of Colorectal Carcinoma**

**Adenocarcinoma**
- Mucinous (colloid) adenocarcinoma (greater than 50% mucin)
- Signet-ring cell carcinoma (greater than 50% signet-ring cells)

**Medullary carcinoma**
- Micropapillary adenocarcinoma
- Serrated adenocarcinoma
- Squamous cell carcinoma
- Adenosquamous carcinoma
- Spindle cell carcinoma
- Poorly differentiated neuroendocrine carcinoma
- Large cell neuroendocrine carcinoma
- Small cell neuroendocrine carcinoma
- Mixed adenoneuroendocrine carcinoma
- Undifferentiated carcinoma

The histologic types of colorectal carcinoma that have been shown to have adverse prognostic significance independent of stage are signet-ring cell carcinoma\(^7\) and small cell carcinoma (poorly differentiated neuroendocrine carcinoma).\(^8\)

Medullary carcinoma is a distinctive histologic type strongly associated with high levels of microsatellite instability (MSI-H), indicative of defects in normal DNA repair gene function. Medullary carcinoma may occur either sporadically or in association with Lynch syndrome.\(^9\)-\(^11\) This tumor type is characterized by solid growth in nested, organoid, or trabecular patterns, with no immunohistochemical evidence of neuroendocrine differentiation. Medullary carcinomas are also characterized by numerous tumor infiltrating lymphocytes and a better prognosis.

Micropapillary carcinoma is characterized by small, tight clusters of tumor cells in cleft-like spaces, and is often present in association with conventional adenocarcinoma. This variant is strongly associated with lymphovascular invasion and lymph node metastasis.\(^12\)

Serrated adenocarcinomas are characterized by neoplastic glands showing prominent serrations, tumor cells with basal nuclei and eosinophilic cytoplasm, and no or minimal luminal necrosis. These tumors are thought to be related to traditional serrated adenomas and may have a more aggressive course than conventional adenocarcinoma.\(^13\)

C. Histologic Grade
A number of grading systems for colorectal cancer have been suggested, but a single widely accepted and uniformly used standard for grading is lacking. Most systems stratify tumors into 3 or 4 grades as follows:

- **Grade 1** Well differentiated (>95% gland formation)
- **Grade 2** Moderately differentiated (50-95% gland formation)
- **Grade 3** Poorly differentiated (<50% gland formation)
- **Grade 4** Undifferentiated (no gland formation or mucin; no squamous or neuroendocrine differentiation)

Despite a significant degree of interobserver variability,\(^14\) histologic grade has been shown to be an important prognostic factor in many studies,\(^15\),\(^16\) with strong correlation between poor differentiation and adverse outcome.\(^17\) While some studies have stratified grade into a two-tiered low- and high-grade system, a three- or four-tier system is more commonly used for gastrointestinal carcinomas. The AJCC has specified use of a four-tiered grading system for colorectal cancer for the 8th edition of the TNM manual.\(^1\) Pathologists should use the four-tier histologic grading scheme as specified above to prevent errors in data recording. As per WHO, the grading scheme applies to adenocarcinoma, not otherwise specified, and not to histologic variants. For example, medullary carcinomas...
behave as low grade tumors even though they may appear poorly differentiated. This grading scheme is also not applicable to poorly differentiated neuroendocrine carcinomas.

D. Carcinoma in an Adenomatous Polyp: Microscopic Tumor Extension and High-Risk Features

Colorectal adenomas containing invasive adenocarcinoma that extends through the muscularis mucosa into the submucosa have been defined as *malignant polyps*. This term encompasses cases in which the entire polyp head is replaced by carcinoma and adenomas with focal malignancy, but the definition excludes adenomas with high-grade dysplasia or intramucosal carcinoma (invasive carcinoma limited to the lamina propria or invading no deeper than the muscularis mucosa), because these polyps possess negligible biological potential for metastasis (see Tis in Note M).

Malignant polyps removed by endoscopic polypectomy require evaluation of histologic factors related to the risk of adverse outcome (ie, lymph node metastasis or local recurrence from residual malignancy) following polypectomy. Factors shown to have independent prognostic significance and are important in determining the need for further surgical treatment include:

- Histologic grade
- Status of the resection margin
- Lymphatic/venous vessel involvement

An increased risk of adverse outcome has been shown to be associated with:

- High-grade carcinoma
- Tumor at or less than 1 mm from the resection margin
- Lymphatic/venous vessel involvement

Reporting of additional histologic factors that have been advocated for assessing risk include tumor budding (note F), depth or area of submucosal invasion. Submucosal involvement has been divided into superficial, mid and deep levels for sessile polyps (Kikuchi levels sm1, sm2 and sm3) for sessile polyps, and into four levels (head, neck, stalk and beyond stalk) in pedunculated polyps (Haggitt levels). Based on measurement, submucosal invasion more than 1 mm has been recognized as an adverse prognostic factor. However, it can be difficult to accurately assess the depth or extent of submucosal involvement due to improper orientation and absence of muscularis propria in these specimens.

E. Lymph-Vascular and Perineural Invasion

It is recommended that small vessel vascular invasion should be reported separately from venous (large vessel) invasion. Small vessel invasion indicates tumor involvement of thin-walled structures lined by endothelium, without an identifiable smooth muscle layer or elastic lamina. Small vessels include lymphatics, capillaries, and postcapillary venules. Small vessel invasion is associated with lymph node metastasis and has been shown to be an independent indicator of adverse outcome in several studies. The higher prognostic significance of extramural small vessel invasion has been suggested, but the importance of anatomic location in small vessel invasion (extramural or intramural) is not well defined.

Tumor involving endothelium-lined spaces with an identifiable smooth muscle layer or elastic lamina is considered venous (large vessel) invasion. Circumscribed tumor nodules surrounded by an elastic lamina on hematoxylin-eosin (H&E) or elastic stain are also considered venous invasion. Venous invasion can be extramural (beyond muscularis propria) or intramural (submucosa or muscularis propria). Extramural venous invasion has been demonstrated by multivariate analysis to be an independent adverse prognostic factor in multiple studies and is a risk factor for liver metastasis. The significance of intramural venous invasion is less clear. Histologic features like tumor deposits adjacent to arterioles (“orphan arteriole” sign) and elongated tumor nodules extending into pericolic fat from the muscularis propria (“protruding tongue” sign) can raise the suspicion for venous invasion. Elastic stain can lead to 2- to 3-fold increase in the detection of venous invasion, and may be used to improve assessment of this feature.

Perineural invasion has been shown to be an independent indicator of poor prognosis. While some series did not find perineural invasion to be a significant predictive factor in stage II disease, many studies have confirmed its adverse effect on survival in stage II disease. Extramural perineural invasion may have a greater adverse
prognostic effect, but the distinction between intramural and extramural perineural invasion has not been well studied.

F. Tumor Budding
The presence of single cells or small clusters of up to five cells at the advancing front of the tumor is considered as peritumoral tumor budding. Numerous studies have shown that high tumor budding in adenocarcinoma arising in polyp is a significant risk factor for nodal involvement, with tumor budding being the most significant factor in some studies. Similarly, the adverse prognosis of high tumor budding has been shown in stage II patients and its inclusion as a high risk factor for making chemotherapy decisions for stage II patients has been advocated. Different criteria for evaluating and reporting tumor budding have been followed in literature. An international tumor budding consensus conference (ITBCC) in 2016 recommended the following criteria for evaluating tumor budding:

1. Tumor budding counts should be done on H&E sections. In cases of obscuring factors like inflammation, immunohistochemistry for keratin can be obtained to assess the advancing edge for tumor buds, but the scoring should be done on H&E sections.
2. Tumor budding should be reported by selecting a “hotspot” chosen after review of all available slides with invasive tumor. The total number of buds should be reported in an area measuring 0.785 mm², which corresponds to 20x field in some microscopes (use appropriate conversion for other microscopes, see table below).
3. Both total number of buds and a three-tier score (based on 0.785 mm² field area) should be reported: low (0-4 buds), intermediate (5-9 buds) and high (10 or more buds).

This is not a required element, but it is recommended that this feature be reported for cancers arising in polyps as well as for stage I and II cases.

<table>
<thead>
<tr>
<th>Eyepiece Magnification: 20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diameter (mm)</strong></td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>18</td>
</tr>
<tr>
<td>19</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>21</td>
</tr>
<tr>
<td>22</td>
</tr>
<tr>
<td>23</td>
</tr>
<tr>
<td>24</td>
</tr>
<tr>
<td>25</td>
</tr>
<tr>
<td>26</td>
</tr>
</tbody>
</table>

Table. ITBCC Normalization Table for Reporting Tumor Budding According to Microscope.
To obtain tumor bud count for your field of view, divide by the normalization number.

G. Polyps
The adenocarcinoma can arise in adenomatous (tubular, tubulovillous, or villous) or serrated (sessile serrated adenoma/polyp or traditional serrated adenoma) polyp. Sessile serrated adenoma often develops cytoplasmic dysplasia resembling tubular adenoma during neoplastic progression. These are presumed to be the precursors of right-sided adenocarcinomas with high levels of microsatellite instability (MSI-H).

H. Perforation
Tumor perforation is an uncommon complication of colorectal cancer, but one that is associated with a poor outcome, including high in-hospital mortality and morbidity. Perforation of the uninvolved colon proximal to an obstructing tumor is also associated with high mortality because of generalized peritonitis and sepsis. Reported perforation rates range from 2.6% to 9%. Perforation is more likely to occur in older patients.
I. Mesorectal Envelope

The quality of the surgical technique is a key factor in the success of surgical treatment for rectal cancer, both in the prevention of local recurrence and in long-term survival. Numerous studies have demonstrated that total mesorectal excision (TME) improves local recurrence rates and the corresponding survival by as much as 20%. This surgical technique entails precise sharp dissection within the areolar plane outside (lateral to) the visceral mesorectal fascia to remove the rectum. This plane encases the rectum, its mesentery, and all regional nodes and constitutes Waldeyer’s fascia. High-quality TME surgery reduces local recurrence from 20% to 30%, to 8% to 10% or less, and increases 5-year survival from 48% to 68%. Adjuvant therapy in the presence of a high-quality TME may further reduce local recurrence (from 8% to 2.6%).

Pathologic evaluation of the resection specimen has been shown to be a sensitive means of assessing the quality of rectal surgery. It is superior to indirect measures of surgical quality assessment, such as perioperative mortality, rates of complication, number of local recurrences, and 5-year survival. Macroscopic pathologic assessment of the completeness of the mesorectum, scored as complete, partially complete, or incomplete, accurately predicts both local recurrence and distant metastasis. Microscopic parameters, such as the status of the circumferential resection margin, the distance between the tumor and nearest circumferential margin (ie, “surgical clearance”), and the distance between the tumor and the closest distal margin, are all important predictors of local recurrence and may be affected by surgical technique.

The nonperitonealized surface of the fresh specimen is examined circumferentially, and the completeness of the mesorectum is scored as described below. The entire specimen is scored according to the worst area.

Incomplete
- Little bulk to the mesorectum
- Defects in the mesorectum down to the muscularis propria
- After transverse sectioning, the circumferential margin appears very irregular

Nearly Complete
- Moderate bulk to the mesorectum
- Irregularity of the mesorectal surface with defects greater than 5 mm, but none extending to the muscularis propria
- No areas of visibility of the muscularis propria except at the insertion site of the levator ani muscles

Complete
- Intact bulky mesorectum with a smooth surface
- Only minor irregularities of the mesorectal surface
- No surface defects greater than 5 mm in depth
- No coning towards the distal margin of the specimen
- After transverse sectioning, the circumferential margin appears smooth

J. Margins

It may be helpful to mark the margin(s) closest to the tumor with ink following close examination of the serosal surface for puckering and other signs of tumor involvement. Margins marked by ink should be designated in the macroscopic description of the surgical pathology report. The serosal surface (visceral peritoneum) does not constitute a surgical margin.

In addition to addressing the proximal and distal margins, the radial margin (Figure 3A-3C) must be assessed for any segment either unencased (Figure 3C) or incompletely encased by peritoneum (Figure 3B) (see Note A). The radial margin represents the adventitial soft tissue margin closest to the deepest penetration of tumor and is created surgically by blunt or sharp dissection of the retroperitoneal or subperitoneal aspect, respectively. Since the lower rectum is entirely extraperitoneal, the radial margin extends circumferentially and has been referred to as the circumferential radial margin. Multivariate analysis has suggested that tumor involvement of the circumferential (radial) margin is the most critical factor in predicting local recurrence in rectal cancer. A positive circumferential (radial) margin in rectal cancer increases the risk of recurrence by 3.5-fold and doubles the risk of
death from disease. For this reason, the circumferential (radial) margin should be assessed in all rectal carcinomas as well as colonic segments with nonperitonealized surfaces. The circumferential (radial) margin is considered negative if the tumor is more than 1 mm from the inked nonperitonealized surface but should be recorded as positive if tumor is located 1 mm or less from the nonperitonealized surface, because local recurrence rates are similar with clearances of 0 to 1 mm. There is limited outcome data for cases with intranodal or intravascular tumor within 1 mm of radial resection margin, but follow-up based on a small number of patients suggests that local recurrence in these tumors may be similar to those with negative margin.44,45

**Figure 3.** A, Mesenteric margin in portion of colon completely encased by peritoneum (dotted line). B, Circumferential margin (dotted line) in portion of colon incompletely encased by peritoneum. C, Circumferential margin (dotted line) in rectum, completely unencased by peritoneum.

The mesenteric resection margin (‘vascular tie’ margin) is the only relevant ‘radial’ margin in segments completely encased by peritoneum (eg, transverse colon). Involvement of this margin should be reported even if tumor does not involve the serosal surface.

Sections to evaluate the proximal and distal resection margins can be obtained either by longitudinal sections perpendicular to the margin or by en face sections parallel to the margin. The distance from the tumor edge to the closest resection margin(s) may also be important, particularly for low anterior resections. For these cases, a distal resection margin of 2 cm is considered adequate; for T1 and T2 tumors, 1 cm may be sufficient distal clearance. Anastomotic recurrences are rare when the distance to the closest margin is 5 cm or greater.

In cases of carcinoma arising in a background of inflammatory bowel disease, proximal and distal resection margins should be evaluated for dysplasia and active inflammation. Proximal, distal, and radial/mesenteric resection margins should be reported in all resections specimens. Deep margin and mucosal margins should be reported in all transanal disk excisions.

**K. Treatment Effect**

 Neoadjuvant chemoradiation therapy in rectal cancer is associated with significant tumor response and downstaging.46 Because eradication of the tumor, as detected by pathologic examination of the resected specimen, is associated with a significantly better prognosis,47 specimens from patients receiving neoadjuvant chemoradiation should be thoroughly sectioned, with careful examination of the tumor site. Minimal residual disease has been shown to have a better prognosis than gross residual disease.48 A modified Ryan scheme is suggested for scoring of tumor response, and has been shown to provide good interobserver reproducibility provide prognostic significance.49 Several other systems have been studied and can be chosen to report the tumor regression score.

<table>
<thead>
<tr>
<th>Modified Ryan Scheme for Tumor Regression Score47</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td>No viable cancer cells (complete response)</td>
</tr>
</tbody>
</table>
Single cells or rare small groups of cancer cells (near complete response) & 1
Residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response) & 2
Extensive residual cancer with no evident tumor regression (poor or no response) & 3

Tumor regression should be assessed only in the primary tumor; lymph node metastases should not be included in the assessment.

Acellular pools of mucin in specimens following neoadjuvant therapy are considered to represent completely eradicated tumor and are not used to assign pT stage or counted as positive lymph nodes.

L. Tumor Deposits
A tumor focus in the pericolic/perirectal fat or in adjacent mesentery (mesocolic or rectal fat) within the lymph drainage area of the primary tumor, but without identifiable lymph node tissue or vascular structure. If the vessel wall or its remnant is identified (H&E, elastic, or any other stain), it should be classified as vascular (venous) invasion, and not as tumor deposit. Similarly, a tumor focus is present in or around a large nerve, should be classified as perineural invasion and not as tumor deposit. Size and shape of the tumor focus are not relevant for classification as a tumor deposit.

The presence of tumor deposits in the absence of any regional node involvement is categorized as N1c, irrespective of T category. Tumor deposits are an adverse prognostic factor\(^{49,50}\) and adjuvant therapy is generally warranted in cases that are categorized as N1c regardless of T classification. The number of tumor deposits should be recorded. If tumor deposits are accompanied by identifiable lymph node metastasis (including micrometastasis), it does not affect the N category, which is then determined by the number of positive lymph nodes (see note M).

In the setting of preoperative or neoadjuvant therapy, the designation of tumor deposit should be used with caution as the tumor foci may represent residual primary tumor with incomplete response.

M. TNM and Anatomic Stage/Prognostic Groupings
Surgical resection remains the most effective therapy for colorectal carcinoma, and the best estimation of prognosis is derived from the pathologic findings on the resection specimen. The anatomic extent of disease is by far the most important prognostic factor in colorectal cancer.

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC)\(^1\) but does not preclude the use of other staging systems.

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal or biopsy of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

TNM Descriptors
For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The
cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

T Category Considerations (Figures 4-6)

pTis. For colorectal carcinomas, carcinoma in situ (pTis) as a staging term refers to tumors involving the lamina propria and/or muscularis mucosae, but not extending through it (intramucosal carcinoma). Tumor extension through the muscularis mucosae into the submucosa is classified as T1 (Figure 5). A synoptic report is required only for invasive tumors, but not Tis.

pT4. Tumors that involve the serosal surface (visceral peritoneum) or directly invade adjacent organs or structures are assigned to the T4 category (Figures 4 and 6).

Figure 4. T4a (left side) with involvement of serosa (visceral peritoneum) by tumor cells in a segment of colorectum with a serosal covering. In contrast, the right side of the diagram shows T3 with macroscopically positive circumferential margin (designated R2 in AJCC staging system), corresponding to gross disease remaining after surgical excision. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al and published by Springer Science and Business Media, LLC, www.springerlink.com.
Figure 5. T1 tumor invades submucosa; T2 tumor invades muscularis propria; T3 tumor invades through the muscularis propria into the subserosa or into nonperitonealized pericolic or perirectal tissues (adventitia). Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al and published by Springer Science and Business Media, LLC, www.springerlink.com.
Figure 6. A, T4b tumor showing direct invasion of coccyx. B, T4b tumor directly invading adjacent loop of small bowel. C, T4a tumor showing gross perforation of bowel through tumor (left). The right-hand panel shows T4b tumor directly invading adjacent bowel. D, T4a tumor with involvement of serosa (visceral peritoneum) by tumor cells. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al and published by Springer Science and Business Media, LLC, www.springerlink.com.

Tumor that is adherent to other organs or structures macroscopically is classified clinically as cT4. However, if no tumor is found within the adhesion microscopically, the tumor should be assigned pT3.

For rectal tumors, invasion of the external sphincter is classified as T3, whereas invasion of the levator ani muscle(s) is classified as T4.

Tumor in veins or lymphatics does not affect the pT classification.

Subdivision of T4 into T4a and T4b. Serosal (visceral peritoneal) involvement by tumor cells (pT4a) has been demonstrated by multivariate analysis to have a negative impact on prognosis, as does direct invasion of adjacent organs (pT4b). Visceral peritoneal involvement can be missed without thorough sampling and/or sectioning, and malignant cells have been identified in serosal scrapings in as many as 26% of specimens categorized as pT3 by histologic examination alone. Although the absence of standard guidelines for assessing peritoneal involvement may contribute to underdiagnosis, the following findings are considered to represent serosal involvement by tumor:

- Tumor present at the serosal surface
- Free tumor cells on the serosal surface (on the visceral peritoneum) with underlying erosion/ulceration of mesothelial lining, mesothelial hyperplasia and/or inflammatory reaction
- Perforation in which the tumor cells are continuous with the serosal surface through inflammation

The significance of tumors that are <1 mm from the serosal surface and accompanied by serosal reaction is unclear, with some but not all studies indicating a higher risk of peritoneal recurrence. Multiple level sections and/or additional section of the tumor should be examined in these cases. If the serosal involvement is not present after additional evaluation, the tumor should be assigned to the pT3 category. The use of elastic stains has been advocated for identification of T4a tumors by demonstrating tumor involvement of the subperitoneal elastic lamina. The elastic stain can be difficult to interpret in this region and the elastic lamina is not uniformly present even in normal colon. Hence routine use of this stain is not considered standard practice. In portions of
the colorectum that are not peritonealized (e.g., posterior aspects of ascending and descending colon, lower portion of rectum), the T4a category is not applicable.

Intramural extension of tumor from one subsite (segment) of the large intestine into an adjacent subsite or into the ileum (e.g., for a cecal carcinoma) or anal canal (e.g., for a rectal carcinoma) does not affect the pT classification. Transmural extension into another organ or site is necessary for T4b designation.

Both types of peritoneal involvement are associated with decreased survival. Although small studies suggested that serosal involvement was associated with worse outcome than invasion of adjacent organs, data from a large cohort of more than 100,000 colon cancer cases indicate that penetration of the visceral peritoneum carries a 10% to 20% better 5-year survival than locally invasive carcinomas for each category of N.

**N Category Considerations**
The regional lymph nodes for the anatomical subsites of the large intestine (Figure 7) are as follows:

- **Cecum**: Pericolic, ileocolic, right colic
- **Ascending colon**: Pericolic, ileocolic, right colic, right branch of middle colic
- **Hepatic flexure**: Pericolic, ileocolic, middle colic, right colic
- **Transverse colon**: Pericolic, middle colic
- **Splenic flexure**: Pericolic, middle colic, left colic
- **Descending colon**: Pericolic, left colic, inferior mesenteric, sigmoid
- **Sigmoid colon**: Pericolic, sigmoid, inferior mesenteric, superior rectal (hemorrhoidal)
- **Rectosigmoid**: Pericolic, sigmoid, superior rectal (hemorrhoidal)
- **Rectum**: Mesorectal, superior rectal (hemorrhoidal), inferior mesenteric, internal iliac, inferior rectal (hemorrhoidal)

![Figure 7](https://example.com/figure7)

**Figure 7.** The regional lymph nodes of the colon and rectum. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Ill. The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al. and published by Springer Science and Business Media, LLC, www.springerlink.com.

For rectal cancers, metastasis in the external iliac or common iliac nodes is classified as distant metastasis.

**Submission of Lymph Nodes for Microscopic Examination.** All grossly negative or equivocal lymph nodes should be submitted entirely. Grossly positive lymph nodes may be partially submitted for microscopic confirmation of metastasis.
The accuracy and predictive value of stage II assignment are directly proportional to the thoroughness of the surgical technique in removing all regional nodes and the pathologic examination of the resection specimen in identifying and harvesting all regional lymph nodes for microscopic assessment. The National Quality Forum lists the presence of at least 12 lymph nodes in a surgical resection among the key quality measures for colon cancer care in the United States (see http://www.facs.org/cancer/qualitymeasures.html).

The likelihood of detecting metastasis increases with the number of lymph nodes examined; hence 12 lymph nodes should be considered the minimum target, but all possible lymph nodes should be retrieved and examined.\textsuperscript{54,55}

The clinical outcome is linked to lymph node harvest in stage II disease,\textsuperscript{56} indicating a positive effect of optimal mesenteric resection by the surgeon, optimal lymph node harvest from the resection specimen by the pathologist, or both.

The number of lymph nodes recovered from a resection specimen is dependent on several factors. Surgical technique, surgery volume, and patient factors (eg, age and anatomic variation) alter the actual number of nodes in a resection specimen, but the diligence and skill of the pathologist in identifying and harvesting lymph nodes in the resection specimen also are major factors. Lymph nodes may be more difficult to identify in specimens from patients who are obese\textsuperscript{57} or elderly, or after neoadjuvant therapy.\textsuperscript{58} Because it has been shown that nodal metastasis in colorectal cancer is often found in small lymph nodes (<5 mm in diameter), diligent search for lymph nodes is required on gross examination of resection specimens. If fewer than 12 lymph nodes are found, re-examining the specimen for additional lymph nodes, with or without visual enhancement techniques, should be considered. The pathology report should clearly state the total number of lymph nodes examined and the total number involved by metastases. Data are insufficient to recommend routine use of tissue levels or special/ancillary techniques.

Nonregional Lymph Nodes. For microscopic examination of lymph nodes in large resection specimens, lymph nodes must be designated as regional versus nonregional, according to the anatomic location of the tumor. Metastasis to nonregional lymph nodes is classified as distant metastasis and designated as M1.

Lymph Nodes Replaced by Tumor. A tumor nodule in the pericolonic/perirectal fat without histologic evidence of residual lymph node tissue is classified as a tumor deposit (peritumoral deposit or satellite nodule) and is not considered a positive lymph node. In the absence of unequivocal lymph node metastases, tumor deposits are recorded as N1c.\textsuperscript{1}

Isolated Tumor Cells. Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters of tumor cells measuring 0.2 mm or less, usually found by special techniques such as immunohistochemical staining, and are classified as N0.\textsuperscript{1} Because the biologic significance of ITCs (either a single focus in a single node, multiple foci within a single or multiple nodes) remains unproven, N0 is considered justified.\textsuperscript{59} The number of lymph nodes involved by ITCs should be clearly stated in a comment section or elsewhere in the report. Metastatic deposits 0.2 mm-2.0 mm have been referred to as micrometastasis. These nodes should be considered as involved by cancer. A separate designation of micrometastasis (N1mi) can be used, but is not necessary.\textsuperscript{1}

Routine assessment of regional lymph nodes is limited to conventional pathologic techniques (gross assessment and histologic examination), and data are currently insufficient to recommend special measures to detect ITCs. Thus, neither multiple levels of paraffin blocks nor the use of special/ancillary techniques such as immunohistochemistry are recommended for routine examination of regional lymph nodes.

TNM Anatomic Stage/Prognostic Groupings
Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible), and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.
## AJCC Stage Groupings

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIC</td>
<td>T4b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1-T2</td>
<td>N1/N1c</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1</td>
<td>N2a</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T3-T4a</td>
<td>N1/N1c</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2-T3</td>
<td>N2a</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T1-T2</td>
<td>N2b</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>T4a</td>
<td>N2a</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3-T4a</td>
<td>N2b</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4b</td>
<td>N1-N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>Any T</td>
<td>Any N</td>
<td>M1a</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>Any T</td>
<td>Any N</td>
<td>M1b</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1c</td>
</tr>
</tbody>
</table>

\(^a\)M0 is defined as no distant metastasis by imaging, etc; no evidence of tumor in distant sites or organs (this category is not assigned by pathologists.)

### N. Ancillary Studies

Universal testing for microsatellite instability and/or status DNA mismatch repair enzymes by immunohistochemistry is recommended by the EGAPP guidelines.\(^{60,61}\) The NCCN guidelines also advocate this approach for patients <70 years. MSI-high cancers are associated with right-sided location, tumor infiltrating lymphocytes, Crohn-like infiltrate, pushing borders, mucinous/signet ring/medullary subtypes, intratumoral heterogeneity (mixed conventional, mucinous, and poorly differentiated carcinoma), high-grade histology, and lack of dirty necrosis.\(^{62,63}\) In view of recommendations for universal testing and chance of missing cases of Lynch syndrome with testing based on Bethesda guidelines,\(^3\) evaluation of histologic features associated with MSI is not required and is no longer included in the synoptic comment.

Since MSI-H cancers have a favorable prognosis, MSI testing for stage II cases can help in making decisions regarding adjuvant chemotherapy. Since MSI-H cancers do not respond well to 5-FU therapy, MSI status is also important in determining the choice of chemotherapeutic regimen.\(^6^4\)

Further details about mismatch repair enzyme immunohistochemistry and PCR for MSI testing, as well as other mutation testing in colorectal cancer (such as KRAS, BRAF) can be found in the CAP Colon and Rectum Biomarkers protocol.

### References


